Ayahuasca Scientific Papers

AEDMP – Asociación para el Estudio y la Divulgación de la Medicina Psicodélica

Research conducted by: Genís Oña -2013-

Asociación para el Estudio y la Divulgación de la Medicina Psicodélica.
Castellarnau, 11 2º 1ª 43004 Tarragona Spain
Tel. 675 55 33 44
Email: medicina.psicodelica@hotmail.com
www.medicinapsicodelica.org

 

Content
_____________________________________
1. What is ayahuasca?

2. Scientific papers about ayahuasca arranged chronologically (1969-2013)

– G. R. Dolmatoff (1969). El contexto cultural de un alucinógeno aborigen : Banisteriopsis Caapi
– C. Grob et al. (1996). Human Psychopharmacology of Hoasca, a Plant Hallucinogen Used in Ritual
Context in Brazil
– J. C. Callaway et al. (1999). Pharmacokinetics of Hoasca Alkaloids in Healthy Humans
– B. Shanon (2000). Ayahuasca and Creativity
– J. Riba et al. (2001). Subjective Effects and Tolerability of the South American Psychoactive
Beverage Ayahuasca in Healthy Volunteers
– J. Riba et al. (2002). Effects of Ayahuasca on Sensory and Sensorimotor Gating in Humans as
Measured by P50 Supression and Prepulse Inhibition of the Startle Reflex, Respectively
– J. Riba et al. (2002). Topographic Pharmaco-EEG Mapping of the Effects of the South American Psychoactive Beverage Ayahuasca in Healthy Volunteers
– E. Frecksa et al. (2003). Effects of Ayahuasca on Binocular Rivalry with Dichoptic Stimulus
Alternation
– J. Riba (2003). Human Pharmacology of Ayahuasca
– D. McKenna (2004). Clinical Investigations of the Therapeutic Potential of Ayahuasca: Rationale
and Regulatory Changes
– J. Riba et al. (2004). Effects of the South American Psychoactive Beverage Ayahuasca on Regional
Brain Electrical Activity in Humans: A Functional Neuroimaging Study Using Low-Resolution
Electromagnetic Tomography
– P. R. Barbosa et al. (2005). Altered States of Consciousness and Short-Term Psychological After-
Effects Induced by the First Time Ritual Use of Ayahuasca in an Urban Context in Brazil
– D. E. Stuckey et al. (2005). EEG Gamma Coherence and Other Correlates of Subjective Reports
During Ayahuasca Experiences
– J. Riba & M. Barbanoj (2005). Bringing Ayahuasca to the Clinical Research Laboratory
– J. Riba et al. (2006). Increased Frontal and Paralimbic Activation Following Ayahuasca, the Pan-
Amazonian Inebriant
– R. Gable (2006). Risk Assessment of Ritual Use of Oral Dimethyltryptamine (DMT) and Harmala
Alkaloids
– E. Rodrigues & E. A. Carlini (2006). Use of South American Plants for the Treatment of
Neuropsychiatric Disorders
– M. Barbanoj et al. (2007). Daytime Ayahuasca Administration Modulates REM and Slow-Wave
Sleep in Healthy Volunteers
– R. G. Santos et al. (2007). Effects of Ayahuasca on Psychometric Measures of Anxiety, Panic-Like
and Hopelessness in Santo Daime Members
– J. H. Halpern et al. (2008). Evidence of Health and Safety in American Members of a Religion Who
Use a Hallucinogenic Sacrament
– P. R. Barbosa et al. (2009). A Six-Month Prospective Evaluation of Personality Traits, Psychiatric
Symptoms and Quality of Life in Ayahuasca-Naïve Subjects
– J. M. Fabregas et al. (2010). Assessment of Addiction Severity Among Ritual Users of Ayahuasca
– J. C. Bouso & J. Riba (2011). An Overview of the Literature on the Pharmacology and
Neuropsychiatric Long Term Effects of Ayahuasca
– D. Frost et al. (2011). B-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau
Phosphorylation at Multiple Alzheimer’s Disease-Related Sites
– R. G. dos Santos et al. (2011). Autonomic, Neuroendocrine, and Immunological Effects of
Ayahuasca
– R. G. dos Santos et al. (2011). Pharmacology of Ayahuasca Administered in Two Repeated Doses
– D. B. de Araujo et al. (2011). Seeing With the Eyes Shut: Neural Basis of Enhanced Imagery
Following Ayahuasca Ingestion
– B. C. Labate (2011). Consumption of Ayahuasca by Children and Pregnant Women: Medical
Controversies and Religious Perspectives
– A. Gaujac et al. (2012). Analytical Techniques for the Determination of Tryptamines and B carbolines in Plant Matrices and in Psychoactive Beverages Consumed During Religious Ceremonies and Neo-shamanic Urban Practices
– E. de Frecksa et al. (2012). Enhancement of Creative Expression and Entoptic Phenomena as After effects of Repeated Ayahuasca Ceremonies
– P. C. Barbosa et al. (2012) Health Status of Ayahuasca Users
– R. Harris & L. Gurel (2012). A Study of Ayahuasca Use in North America
– E. H. McIlhenny (2012). Ayahuasca Characterization, Metabolism in Humans, and Relevance to
Endogenous N,N-Dimethyltryptamines
– J. C. Bouso et al. (2012). Personality, Psychopatology, Life Attitudes and Neuropsychological
Performance Among Ritual Users of Ayahuasca: A Longitudinal Study
– G. Oña (2012). Ayahuasca. Una medicina que cambia nuestra vida.
– R. G. dos Santos (2013). Safety and Side Effects of Ayahuasca in Humans – An Overview Focusing
on Developmental Toxicology
– J. C. Bouso et al. (2013). Acute Effects of Ayahuasca on Neuropsychological Performance:
Differences in Executive Function Between Experienced and Occasional Users
– G. Thomas et al. (2013). Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary
Observational Study in Canada

– D. E. Rosenberg et al. (1964). The Effect of N,N-Dimethyltryptamine in Human Subjects Tolerant
to Lysergic Acid Diethylamide
– D. M. Ruffing & E. F. Domino (1981). Effects of Selected Opioid Agonists and Antagonists on
DMT- and LSD-25-Induced Disruption of Food-Rewarded Bar Pressing Behavior in the Rat
– D. M. Stoff et al. (1982). Interaction of Monoamine Blocking Agents With Behavioral Effects of
N,N Dimethyl-tryptamine
– R. J. Strassman et al. (1994). Dose-Response Study of N,N-Dimethyltryptamine in Humans
– R. J. Strassman et al. (1996). Differential Tolerance to Biological and Subjective Effects of Four
Closely Spaced Doses of N,N-Dimethyltryptamine in Humans
– R. J. Strassman (1996). Human Psychopharmacology of N,N-Dimethyltryptamine
– J. C. Callaway et al. (1996). Quantitation of N,N-Dimethyltryptamine and Harmala Alkaloids in
Human Plasma After Oral Dosing With Ayahuasca
– E. Gouzoulis-Mayfrank et al. (2005). Psychological Effects of (S)-Ketamine and N,N Dimethyl-tryptamine (DMT) : A Double-Blind, Cross-Over Study in Healthy Volunteers
– K. Heekeren et al. (2007). Prepulse Inhibition of the Startle Reflex and its Attentional Modulation
in the Human S-Ketamine and N,N-Dimethyltryptamine (DMT) Models of Psychosis
– N. V. Cozzi et al. (2009). Dimethyltryptamine and Other Hallucinogenic Tryptamines Exhibit
Substrate Behavior at the Serotonin Uptake Transporter and the Vesicle Monoamine Transporter
– D. Fontanilla et al. (2009). The Hallucinogen N,N-Dimethyltryptamine (DMT) is an Endogenous
Sigma-1 Receptor Regulator
– V. Cakic et al. (2010). Dimethyltryptamine (DMT): Subjective Effects and Patterns of Use Among
Australian Recreational Users
– TP Su et al. (2011). When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine
Meets the Sigma-1 Receptor
– J. Riba et al. (2012). Metabolism and Disposition of N,N-Dimethyltryptamine and Harmala
Alkaloids After Oral Administration of Ayahuasca
– S. A. Barker et al. (2012). A Critical Review of Reports of Endogenous Psychedelic N,N Dimethyl-tryptamine in Humans: 1955-2010
– E. de Frecksa et al. (2013). A Possibly Sigma-1 Receptor Mediated Role of Dimethyltryptamine in
Tissue Protection, Regeneration, and Immunity
– A. Gaujac et al. (2013). Determination of N,N-Dimethyltryptamine in Beverages Consumed in Religious Practices by Headspace Solid-Phase Microextraction Followed by Gas Chromatography Ion Trap Mass Spectrometry
– S. A. Barker et al. (2013). LC/MS/MS Analysis of the Endogenous Dimethyltryptamine Hallucinogens, Their Precursors, and Major Metabolites in Rat Pineal Gland Microdialysate

What is Ayahuasca?

Ayahuasca it’s the most investigated amazon psychedelic. Depending the region in the jungle where you are, ayahuasca will called by different names (Caapi, Yagé, etc.). This beverage is the result of a decoction of two plants: Ayahuasca (Banisteriopsis Caapi) and Chakruna (Psychotria Viridis) . The first plant contains B-carboline compounds (Harmine, tetrahidroharmine and harmaline), which act as powerful inhibitors of monoamine oxidase-A (MAOI-A). The second plant contains DMT (N,N Dimethyl-tryptamine). Although DMT is a strong psychedelic, it’s not psychoactive orally, because our MAO degrades it in the liver, and partially in the stomach. However, with the MAOI of the first plant, DMT can work normally.